Diagnosing early onset dementia typically takes about 3.4 years from the first symptoms to a definitive diagnosis, largely because cognitive decline in people under 65 is rarely the first thing doctors suspect. The process involves layers of testing: cognitive screening, brain imaging, blood work, and sometimes spinal fluid analysis, all aimed at confirming dementia and ruling out psychiatric or medical conditions that can mimic it.
Early onset (also called young onset) dementia refers to any dementia diagnosed before age 65. Because symptoms often emerge during peak working years, the signs tend to surface differently than in older adults, and the path to diagnosis is more complicated.
Why Diagnosis Takes So Long
The average time from first symptoms to diagnosis is roughly 3.4 years for younger patients, and several factors push that number higher. Younger age at symptom onset is itself a predictor of delay, simply because clinicians are less likely to consider dementia in someone in their 40s or 50s. When the dementia type is something other than Alzheimer’s disease, the delay increases by about five months on average. And each additional specialist a patient is referred to before reaching the right one adds roughly six more months.
Specialized young onset dementia services, where they exist, cut about 12 months off the diagnostic timeline. But most people don’t start there. They start with a primary care doctor, who may first explore depression, stress, burnout, or other explanations before referring to a neurologist.
The Initial Clinical Assessment
The diagnostic process begins with a detailed health history. Your doctor will ask about the specific changes you or your family have noticed, when they started, and how they’ve progressed. They’ll want to know about your family’s medical history, any medications you take, and your mental health history. This conversation matters more than it might seem, because the pattern of symptoms helps point toward a specific type of dementia.
Alzheimer’s disease, for example, usually starts with difficulty learning and retaining new information. Frontotemporal dementia (FTD) more often begins with personality or behavioral changes: social inappropriateness, apathy, impulsiveness, or compulsive repetitive behaviors. A person with early FTD may still know the date and keep track of recent events just fine, while struggling with judgment and empathy. These distinctions guide every step of testing that follows.
Cognitive Testing
In-office cognitive screening is one of the first concrete steps. The most commonly used tools test memory, attention, language, and problem-solving, but not all screens are equally useful for catching early changes.
The Mini-Mental State Examination (MMSE), one of the oldest and most familiar screening tools, is often not sensitive enough to detect early cognitive decline. The Montreal Cognitive Assessment (MoCA) performs better for identifying both mild cognitive impairment and dementia. Some screenings are surprisingly simple: in one common task, you’re asked to name as many animals as you can in 60 seconds. People with dementia are 25 times more likely to name fewer than 10.
If these initial screens raise concerns, your doctor will likely refer you for a full neuropsychological evaluation. A neuropsychologist administers a much more detailed battery of tests, sometimes lasting several hours, that measures specific cognitive abilities: verbal memory, visual memory, processing speed, executive function, language fluency, and more. The resulting profile helps distinguish between dementia types and can also clarify whether cognitive symptoms stem from a mood disorder rather than a neurodegenerative process. Neuropsychologists then compile a comprehensive report that becomes a key piece of the diagnostic puzzle.
Ruling Out Conditions That Mimic Dementia
One of the biggest challenges in diagnosing early onset dementia is that several psychiatric and medical conditions look remarkably similar, especially in younger people. Depression is a common source of confusion, because it can cause significant problems with concentration, motivation, and memory. FTD in particular is frequently misdiagnosed as depression when behavioral symptoms like apathy and social withdrawal are the primary features.
In younger patients, FTD may also be confused with schizophrenia, bipolar disorder, or obsessive-compulsive disorder. The repetitive, compulsive behaviors common in the behavioral variant of FTD can closely resemble OCD. And because the neurological exam and personal history of someone with a psychiatric disorder and someone with FTD can look strikingly similar, brain imaging and neuropsychological testing are often what finally clarifies the picture.
Blood and urine tests help rule out other reversible causes of cognitive decline: thyroid dysfunction, vitamin deficiencies, infections, liver or kidney problems, and medication side effects.
Brain Imaging
MRI is typically the first imaging study ordered. It can reveal patterns of brain shrinkage (atrophy) that point toward specific dementia types, rule out tumors or strokes, and support or weaken a suspected diagnosis. In FTD, for instance, the frontal and temporal lobes show disproportionate shrinkage compared to the rest of the brain.
When the diagnosis remains unclear, functional brain scans like FDG-PET may be used. This type of scan measures how actively different brain regions are using energy, and different dementias produce distinct patterns. Alzheimer’s disease, frontotemporal dementia, Lewy body dementia, and vascular dementia each show characteristic areas of reduced or altered brain activity, helping clinicians differentiate between them with greater confidence.
Amyloid PET scans take this a step further by directly detecting the amyloid plaques that are a hallmark of Alzheimer’s disease. A negative amyloid PET scan can effectively rule out Alzheimer’s as the cause of someone’s symptoms, which is particularly useful when the presentation is atypical.
Spinal Fluid and Blood Biomarkers
Cerebrospinal fluid (CSF) testing, done through a lumbar puncture, can measure proteins that reflect the specific brain changes happening in Alzheimer’s disease. The key markers are a type of amyloid protein (which drops in the spinal fluid when it’s accumulating in the brain instead) and two forms of tau protein (which rise as brain cells are damaged). Together, these biomarkers can confirm or exclude Alzheimer’s pathology with greater certainty than clinical assessment and imaging alone, and they can detect changes even before symptoms become obvious.
A newer and less invasive option is now available. In May 2025, the FDA cleared the first blood test for diagnosing Alzheimer’s disease. The test measures a ratio of phosphorylated tau and amyloid proteins in blood plasma. In clinical studies, 91.7% of people who tested positive were confirmed to have amyloid plaques by PET scan or CSF testing, and 97.3% of those who tested negative were confirmed negative. Fewer than 20% of patients received an indeterminate result. The test is approved for adults 55 and older showing signs of cognitive decline, and it’s not intended as a standalone diagnostic tool, but as one piece of a broader workup.
Genetic Testing
A small percentage of early onset Alzheimer’s cases are caused by inherited gene mutations that virtually guarantee the disease will develop before age 65. Three genes are involved: APP, PSEN1, and PSEN2. A person who inherits a disease-causing variant of any one of these from either parent is likely to develop symptoms.
Genetic testing is not routine for everyone being evaluated for dementia. It’s most relevant when there’s a strong family history of early onset Alzheimer’s, particularly if multiple family members developed the disease in their 40s or 50s. The results carry significant implications not just for the person tested but for their biological relatives, so genetic counseling is part of the process.
How the Pieces Come Together
No single test diagnoses early onset dementia. The diagnosis is built from converging evidence: the clinical history, the pattern of cognitive strengths and weaknesses on neuropsychological testing, the imaging findings, and biomarker results when available. A neurologist or dementia specialist synthesizes all of this, often in collaboration with neuropsychologists and other team members, to reach a diagnosis and identify the specific type of dementia involved.
Getting to the right specialist matters. Seeing a clinician or team with specific experience in young onset dementia can shave a full year off the diagnostic timeline, and the accuracy of the diagnosis improves when neuropsychological testing, imaging, and biomarker analysis are interpreted together rather than in isolation. If your initial provider isn’t finding answers, asking for a referral to a memory clinic or academic medical center with a dedicated dementia program is a reasonable next step.